Jupiter Neurosciences, Inc. (JUNS) - 10-K Summary
Business Context and Reporting Period
Company: Jupiter Neurosciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Reporting Date: March 28, 2025
Business Overview: Jupiter is a clinical-stage research and development company focused on JOTROL, an enhanced oral formulation of resveratrol designed to treat neuro-inflammation. Primary targets include Parkinson's Disease, Mild Cognitive Impairment/early Alzheimer's Disease, and rare diseases such as Friedreich's ataxia, Mucopolysaccharidosis Type 1 (MPS I), and MELAS syndrome. The company operates as a single reportable segment.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,439,625) | $(4,783,689) |
| Cash Flow from Operations | $(3,911,004) | $(480,953) |
| Cash and Cash Equivalents (End of Period) | $3,769,510 | $28,478 |
| Accumulated Deficit | $(26,022,129) | $(23,582,504) |
| Outstanding Debt (Principal) | $146,432 (Related Party) | $383,479 (Related Party) |
Note: The company generated no revenue from product sales in either period. The significant increase in cash in 2024 was driven by an Initial Public Offering (IPO) in December 2024.
Material Changes vs. Prior Period
- Capital Raise: In December 2024, the company completed a registered public offering of 2,750,000 shares at $4.00 per share, yielding net proceeds of approximately $9.7 million. This significantly improved liquidity compared to the $28,478 cash balance at the end of 2023.
- Debt Repayment: Proceeds from the IPO were used to fully repay a Senior Secured Convertible Note (approx. $2.1 million) and Convertible Debt III (approx. $178,000). As of December 31, 2024, no convertible notes remained outstanding.
- Operating Expenses: Total operating expenses decreased from $3.87 million in 2023 to $3.09 million in 2024. Research and Development (R&D) expenses dropped significantly from $954,793 to $492,660, while General and Administrative (G&A) expenses decreased slightly from $2.92 million to $2.60 million.
- Non-Cash Items: The company recorded a gain on extinguishment of debt of $857,723 in 2024, compared to a loss of $887,946 in 2023, largely due to the repayment and modification of debt instruments.
Guidance, Outlook, and Risks
Clinical Outlook:
- Parkinson's Disease (JNS115): The company plans to initiate a Phase IIa clinical trial in Q3 2025, with results expected approximately 12 months later.
- Alzheimer's/MCI (JNS108): A grant application for a Phase II trial is pending with the National Institute on Aging (NIA), with a decision expected in May 2025. Failure to secure this funding could delay the program.
- Rare Diseases: No specific timelines set for Friedreich's ataxia, MPS I, or MELAS trials, though the company holds Orphan Drug Designation for Friedreich's ataxia.
Strategic Initiatives:
- Asia Expansion: Entered into service agreements with Asian partners (Optimize Wellness, Regis Healthcare, Longevity Technology) paid for via stock issuance to accelerate development and potential out-licensing in South-East Asia.
- Consumer Products: Announced a partnership with Aquanova AG to launch nutritional products targeting longevity and aging in Q3 2025 via a Direct-to-Consumer model.
Material Risks:
- Going Concern: Management has concluded that factors raise substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows, despite the recent IPO. The auditor has included an explanatory paragraph regarding this uncertainty.
- Capital Requirements: The company will require substantial additional capital to fund clinical trials and operations. Failure to raise capital could force delays or termination of programs.
- Nasdaq Compliance: As of March 21, 2025, the company received notice of non-compliance with Nasdaq's minimum bid price requirement ($1.00). It has 180 days (until September 17, 2025) to regain compliance or face delisting.
- Third-Party Dependence: Reliance on third parties for manufacturing, clinical trials, and Asian market development creates execution risks.
Key Facts for Investor Verification
- Going Concern Status: Verify the company's specific plan to generate positive cash flow or secure additional financing to address the auditor's "substantial doubt" qualification.
- Nasdaq Delisting Risk: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement by September 17, 2025, to avoid delisting.
- NIA Grant Decision: Track the May 2025 decision on the $16.5 million grant application for the Alzheimer's/MCI Phase II trial, as this is critical for funding that specific program.
- Asian Service Agreements: Review the performance of the Asian partners (paid via stock) to ensure services are delivered as agreed, given the risk of non-performance without cash recourse.
- Cash Burn Rate: Assess the runway provided by the $3.77 million cash balance against the projected costs of the upcoming Parkinson's Phase IIa trial and general operations.